Publish in OALib Journal
APC: Only $99
cell lung cancer [SCLC] is a devastating form of cancer, with most patients
harbouring extensive disease at diagnosis and survival of less than 5% at five
years. Progress in novel therapies has been limited. This specialist review
explores current targeted therapy options and potential areas of development.